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Abstract 27 
Importance. Attention Deficit Hyperactivity Disorder (ADHD) is a highly heritable 28 
neurodevelopmental disorder that shows clinical and genetic overlap with other 29 
childhood neurodevelopmental problems. ADHD symptom levels typically decline 30 
across childhood/adolescence, although remain elevated for some individuals. The 31 
determinants of symptom persistence and decline are not yet fully understood.  32 
Objective. Test the hypothesis that genetic risk variant load for ADHD (indexed by 33 
polygenic risk scores (PRS)), but not for other psychiatric disorders, is associated 34 
with population-based ADHD symptom trajectories across childhood/adolescence. 35 
As a secondary objective, examine whether higher ADHD genetic liability is 36 
correlated with childhood multi-morbidity (total number of additional 37 
neurodevelopmental problems). 38 
Design, setting and participants. A prospective population-based cohort design, 39 
The Avon Longitudinal Study of Parents and Children (ALSPAC): ongoing data 40 
collection since 1990. 14,701 children were alive at 1 year, 9575 individuals with 41 
data on ADHD symptoms at multiple time-points were included.  42 
Main Outcome and Measure(s). ADHD symptom trajectories from ages 4 to 17 43 
years (7 time-points). The primary exposure variables, PRS, were generated in 44 
ALSPAC using genome-wide association study results from the Psychiatric 45 
Genomics Consortium. Childhood multi-morbidity scores (age 7-9 years) were 46 
measured by total impairments (0-4) in four domains known to share genetic liability 47 
with ADHD: (i) IQ, (ii) Social-communication, (iii) Pragmatic language, and (iv) 48 
Conduct. 49 
Results. Four ADHD symptom trajectories were identified: low (82.6%), intermediate 50 
(7.7%), childhood-limited (5.8%) and persistent (3.9%). ADHD PRS were higher in 51 
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the persistent compared to each of the other 3 trajectories (χ2(1)=4.70-14.67, 52 
p<0.001-0.03, OR=1.22-1.31). Findings were specific to ADHD PRS; other 53 
psychiatric PRS did not differ across trajectories. Multi-morbidity was also highest in 54 
the persistent trajectory (χ2(1)= 31.16-136.85, p<0.001, OR=1.90-6.83) and was 55 
associated with persistence independent of PRS.  56 
Conclusions and Relevance. ADHD symptom persistence across 57 
childhood/adolescence in the general population is associated with higher ADHD 58 
PRS. Childhood multi-morbidity was also associated with persistence and may help 59 
to identify children with ADHD whose symptoms are most likely to continue into 60 
adolescence. 61 
 62 
Keywords: ALSPAC; ADHD; trajectories; polygenic risk scores; genetic; 63 
multimorbidity; longitudinal 64 
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Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder 67 
that has its onset in childhood.1-3 Although considered to manifest most commonly in 68 
children, around 15% of people with a childhood diagnosis continue to meet clinical 69 
criteria for ADHD in adult life, with up to 65% showing sub-threshold ADHD.4 70 
Furthermore, recent work suggests that for some individuals, ADHD emerges newly 71 
in adult life,5-7 highlighting the need to investigate the natural history of ADHD in 72 
general population samples. While ADHD is relevant across the lifespan, most 73 
children show a decline in symptom levels across childhood/ adolescence - a feature 74 
of other childhood-onset neurodevelopmental disorders such as autism spectrum 75 
disorder, communication and specific learning disorders.1 The determinants of 76 
neurodevelopmental disorder persistence are not fully understood, although for 77 
ADHD, initial symptom severity, comorbidities, cortical maturation and familial 78 
loading among other factors have been considered as contributors.8-15  79 
ADHD is highly heritable with a heritability estimate of 71-90%.16 Twin studies 80 
suggest that ADHD symptom persistence is also highly heritable, but it has only 81 
recently become possible to directly assess genetic contributions.8,17-19 Genomic 82 
studies of ADHD have revealed a genetic architecture of multiple common risk 83 
alleles as well as rare mutations.16 Although individual common risk alleles typically 84 
have small effect sizes for multifactorial disorders like ADHD, composite measures - 85 
polygenic risk scores (PRS) - representing an individual’s estimated total burden of 86 
common risk alleles (where risk alleles are defined by their association statistics and 87 
effect sizes in a discovery GWAS) have been found to be useful biological indicators 88 
of disease risk.19 ADHD PRS are higher in patients with disorder than controls21 and 89 
are associated with ADHD symptom levels in the general population.22,23 ADHD also 90 
shares genetic liability with other neurodevelopmental traits and conduct 91 
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problems,1,21,24 suggesting that those with higher ADHD genetic loading are likely to 92 
manifest elevated levels in these domains.  93 
We set out to examine the relationships between psychiatric PRS and 94 
population-based developmental trajectories of ADHD symptoms from early 95 
childhood to adolescence. We hypothesized that PRS for ADHD, but not for other 96 
psychiatric disorders (schizophrenia, bipolar disorder, depression) would be 97 
associated with ADHD symptom persistence from ages 4 to 17 years. We also 98 
postulated that a trajectory of persistent ADHD symptoms would be associated with 99 
a higher burden of childhood neurodevelopmental impairments and conduct 100 
problems, as this "multi-morbidity" would index underlying ADHD genetic liability. 101 
Method 102 
Sample 103 
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a well-104 
established prospective, longitudinal birth cohort study. The enrolled core sample 105 
consisted of 14,541 mothers living in Avon, England, who had expected delivery 106 
dates of between 1st April 1991 and 31st December 1992. Of these pregnancies 107 
13,988 children were alive at 1 year. When the oldest children were approximately 7 108 
years of age, the initial sample was increased by recruiting eligible families who had 109 
failed to join the study originally, resulting in an additional 713 children being 110 
enrolled. The resulting total sample size of children who were alive at 1 year was 111 
N=14,701. Ethical approval for the study was obtained from the ALSPAC Ethics and 112 
Law Committee and the Local Research Ethics Committees. All participants provided 113 
written informed consent. Full details of the study, measures and sample can be 114 
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found elsewhere25,26 (see http://www.bris.ac.uk/alspac/researchers/data-115 
access/data-dictionary). Where families included multiple births, we included the 116 
oldest sibling. Individuals were included in our analyses where primary data on 117 
ADHD symptoms (see below) were available for at least two time-points: N=9575. 118 
The numbers of individuals with data at different time-points are given in the 119 
Supplementary Materials. 120 
ADHD symptoms 121 
The primary outcome was ADHD symptoms assessed repeatedly across time using 122 
the parent-rated 5-item Strengths and Difficulties Questionnaire (SDQ)27 subscale 123 
designed to measure hyperactive-inattentive symptoms (range 0-10). In-line with 124 
recommendations and to maintain consistency with previous work in ALSPAC,27,28 125 
abnormal scores were defined as those ≥7 and borderline scores as those=6. The 126 
SDQ showed high sensitivity/specificity for detecting a DSM-IV diagnosis of ADHD 127 
assessed using a diagnostic interview at age 7 years (see Supplementary Materials). 128 
Data were available from parent reports at ages 47, 81, 97, 115, 140, 157 and 198 129 
months: roughly age 4 to 17 years.  130 
Polygenic risk scores 131 
PRS were generated as the standardized mean number of disorder risk alleles in 132 
approximate linkage equilibrium (R2<0.25), weighted by GWAS allele effect size (see 133 
below), derived from dosage data of imputed autosomal SNPs using standard 134 
procedures.20 Risk alleles were defined as those associated with case-status in the 135 
Psychiatric Genomics Consortium (PGC) analyses of several phenotypes at a 136 
threshold of p<0.5 for ADHD, bipolar disorder and depression and p<0.05 for 137 
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schizophrenia (these thresholds maximally capture phenotypic variance29-34) (GWAS 138 
case/control sample sizes: ADHD 5,621/13,589; schizophrenia 35,476/46,839; 139 
bipolar disorder 7,481/9,250; depression 9,240/9,519 respectively). Genotyping and 140 
full PRS details are given in the supplementary materials. Power was estimated 141 
using the Dudbridge calculator with approximations for some of the required 142 
parameters.35  143 
Other characteristics 144 
We investigated whether the burden of co-occurring neurodevelopmental and 145 
conduct problems in childhood (at age 7-9 years) are associated with ADHD genetic 146 
liability (defined by PRS). Problems (defined categorically using established cut-147 
points to enable computation of "multi-morbidity”) included: (i) Low IQ - Wechsler 148 
Intelligence Scale for Children IQ <80.36 (ii) Social-communication problems - parent-149 
rated Social and Communication Disorders Checklist ≥9.37 (iii) Pragmatic language 150 
impairment - parent-rated Children’s Communication Checklist subscale ≤132.38 (iv) 151 
Conduct problems - parent-rated SDQ subscale ≥4 (91 months).27 Multi-morbidity 152 
was defined as the sum of the number of impairments in domains i-iv (range 0-4). 153 
Statistical analysis 154 
Latent class growth analysis (LCGA) was conducted in Mplus39 to identify ADHD 155 
developmental trajectories across all 7 time-points, using binary ADHD symptom 156 
data, in-line with previous work in ALSPAC.28 LCGA aims to group individuals into 157 
categories (“classes”) based on different patterns of change (growth curves) across 158 
multiple time-points, with within-class covariance matrices fixed to zero (i.e. 159 
individuals within the same class are specified to have the same growth curve).40 160 
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Starting with a single k-class solution, k+1 solutions are fitted until the optimum 161 
solution is reached. Models were run using a robust maximum likelihood parameter 162 
estimator and full information maximum likelihood (FIML) estimation.39 The optimal 163 
number of categories was determined using adjusted Bayesian information criterion 164 
(BIC) to assess model fit and entropy to assess classification accuracy. Differences 165 
in PRS and multi-morbidity were assessed by a Wald test of equality of means using 166 
posterior probability based multiple imputations (ORs were generated using 167 
multinomial logistic regressions),41 which takes profile measurement error into 168 
account (PRS and multi-morbidity were not used to generate the trajectories). Finally 169 
we investigated the independent associations of ADHD PRS and multi-morbidity with 170 
class membership using a bias-free three-step approach (R3STEP)42 that performs 171 
better than conventional 3-step methods.43 172 
Results 173 
ADHD symptom trajectories 174 
LCGA indicated the 4-class solution of ADHD trajectories to have the best model fit 175 
(adjusted BIC=25574.45; Vuong-Lo-Mendell-Rubin likelihood ratio test p<0.001 176 
compared to a 3-class solution) and classification accuracy (entropy=0.82), 177 
consistent with previous work in ALPSAC.28 As shown in Figure 1, this included the 4 178 
classes: low (82.6%), intermediate (7.7%), childhood-limited (5.8%) and persistent 179 
(3.9%). The solution did not include an adolescent-onset group. The proportion of 180 
males differed across the trajectories, with the largest proportion in the persistent 181 
(72.9%), smallest in the low (48.0%) and intermediate levels in the child-limited and 182 
intermediate trajectories (62.3% and 63.0% respectively) (overall χ2(3)=45.22, 183 
p<0.001).  184 
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Genetic variables: psychiatric polygenic risk scores 185 
As shown in Table 1, ADHD polygenic risk scores differed across the four 186 
trajectories; scores were highest in the persistent trajectory, lowest for the low 187 
symptom group and intermediate for the other two classes. Differences were 188 
observed for the persistent trajectory when compared separately to the childhood-189 
limited group (χ2=6.50, p=0.01, OR=1.26), intermediate (χ2=4.70, p=0.03, OR=1.22) 190 
and the low trajectory class (χ2=14.67, p<0.001, OR=1.31). The association with 191 
trajectory was specific to the ADHD PRS: PRS for schizophrenia, bipolar disorder 192 
and depression were not associated with ADHD symptom trajectories (see Table 1). 193 
Childhood multi-morbidity 194 
The proportion of individuals with neurodevelopmental and conduct problems across 195 
the 4 trajectories are shown in Table 2. Low IQ, social-communication problems, 196 
pragmatic language impairment and conduct problems at ages 7-9 years all differed 197 
by class (χ2(3)=12.76-103.50, p<0.001-0.005), with highest levels in the persistent 198 
class compared to all other classes (χ2(1)=6.73-225.86, p<0.001-0.009). The 199 
childhood-limited and intermediate trajectories also showed elevated levels 200 
compared to the low class.  201 
The proportions of individuals with multi-morbidities across the 4 trajectories 202 
are shown in Table 2. Multi-morbidity varied by latent class trajectory (more than 1 203 
neurodevelopmental/conduct domain affected χ2(3)=38.93, p<0.001; more than 2 204 
domains χ2(3)=17.31, p=0.001) with a higher burden of childhood 205 
impairments/problems in the persistent class compared to all other classes (total 206 
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multi-morbidity χ2(1)=31.16-136.85, p<0.001, OR=1.90-6.83) and elevated levels in 207 
the childhood-limited and intermediate compared to the low class.  208 
Independent contributions of ADHD PRS and childhood multi-morbidity to ADHD 209 
persistence  210 
Multi-morbidity at age 7-9 years was associated with ADHD PRS (OR=1.16, 211 
p<0.001) but not with PRS for schizophrenia, bipolar disorder or depression 212 
(OR=1.02-1.09, p>0.05). 213 
Persistent vs. low class. When entered simultaneously (N=3688), both multi-214 
morbidity and ADHD PRS were independently associated with persistent class 215 
membership compared to the low class (multi-morbidity B=2.22, SE=0.15, p<0.001, 216 
OR per additional neurodevelopmental/conduct domain= 9.21; PRS B=0.35, 217 
SE=0.13, p=0.01, OR per standard deviation increase in ADHD PRS = 1.42).. 218 
 Persistent vs. childhood-limited class. There was also evidence that multi-219 
morbidity was independently associated with ADHD persistence relative to the 220 
childhood-limited class (B=0.38, SE=0.14, p=0.01, OR per additional 221 
neurodevelopmental/conduct domain= 1.46), whereas evidence for ADHD PRS was 222 
weak (B=0.26, SE=0.18, p=0.14, OR per standard deviation increase in ADHD PRS 223 
= 1.30). 224 
Grouping individuals using ADHD cut-points at two time-points 225 
Given recent findings on "adolescent-onset" ADHD,5-7 in a post-hoc investigation we 226 
categorized individuals as showing ADHD symptom persistence if they scored above 227 
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the SDQ ADHD subscale cut-point at two time-points: ages 7 and 17 years (N=4824; 228 
individuals with data on ADHD symptoms at both time-points).  229 
Most individuals did not meet the threshold for high levels of ADHD symptoms 230 
at either age and were categorized as low (N=4193, 86.9%). Around 10% of 231 
individuals (N=481) met the cut-point at age 7; the majority of these no longer met 232 
the cut-point at age 17 and were categorized as child-limited (N=370, 7.7%), with 233 
those meeting the cut-point at both ages categorized as persistent (N=106, 2.2%). 234 
Around three percent (N=155) did not meet the threshold for high levels of ADHD 235 
symptoms at ages 7, but did at age 17 years (.3% had borderline levels of ADHD 236 
traits at age 7 years).27 We categorised an adolescent-onset subgroup as those who 237 
met the abnormal cut-point at age 17 but did not have borderline or abnormal 238 
symptoms at age 7: (N=122; 2.5% of the total sample).  239 
As shown in Table 3, ADHD PRS differed across the four ADHD groups 240 
(F(3,3644)=3.01, p=0.03) but PRS for schizophrenia, bipolar disorder and 241 
depression did not (F(3,3644)=0.66-2.01, p=0.11-0.58). Specifically, there was 242 
evidence of higher ADHD PRS in the persistent compared to the low subgroup 243 
(B=0.29, SE=0.11, p=0.01, OR per standard deviation increase in ADHD PRS = 244 
1.34), as shown in Figure 2. Follow-up analyses categorizing individuals using (i) age 245 
4 and 17 year symptoms, (ii) age 12 and 17 year symptoms, (iii) inattentive and 246 
hyperactive/impulsive traits separately - all revealed the same pattern of results 247 
(shown in Supplementary Materials).  248 
Discussion 249 
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This study aimed to test the hypothesis that ADHD common risk allele burden as 250 
indexed by polygenic risk scores (PRS) contributes to population-based ADHD 251 
developmental trajectories from early childhood to adolescence. Defining 252 
susceptibility alleles for a range of psychiatric disorders from large patient case-253 
control discovery samples,29-34 we found that in a population-cohort, higher ADHD 254 
PRS were associated with persistence of ADHD symptoms but that other psychiatric 255 
genetic risk scores were not. The persistent trajectory also had the highest burden of 256 
multi-morbidity for neurodevelopmental and conduct problems in childhood.  257 
While ADHD typically onsets - and is thought to be most common - in 258 
childhood, around 15% of children with a childhood diagnosis show persistence 259 
across childhood and adolescence and still meet diagnostic criteria for ADHD in 260 
adulthood4 while only around 35% achieve full remission.2,4 In-line with this, and 261 
previous work in the ALSPAC population cohort,28 we identified two trajectory groups 262 
of individuals with a high probability of having initially elevated ADHD symptoms in 263 
childhood (total 9.7%). Of these, around 40% were estimated to be in the persistent 264 
trajectory, with a high probability of elevated ADHD traits at age 17 years old. The 265 
other 60% were estimated to be in a childhood-limited trajectory, with a low 266 
probability of high ADHD traits after around age 10. 267 
We found that ADHD genetic risk scores were higher specifically in the 268 
trajectory with persistent symptoms compared to those with consistently low 269 
symptoms and childhood-limited symptoms. Twin studies that indirectly infer genetic 270 
contributions, have suggested that most of the persistence in ADHD symptoms is 271 
explained by additive genetic variance and is highly heritable.8,17-19 Those with 272 
persistent ADHD also have a higher familial load with almost a 4-fold higher risk of 273 
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illness in their families than individuals with childhood ADHD.18,44 Some twin studies 274 
suggest that different genetic risk factors are associated with persistence - compared 275 
to the baseline levels - of ADHD traits.45 Our work suggests that common genetic 276 
variants associated with ADHD diagnosis contribute to the persistence of ADHD 277 
traits in the general population, as well as initial childhood levels, found in previous 278 
work.22,24 The finding that ADHD PRS were higher in those with persistent vs. 279 
childhood-limited symptoms is novel and potentially clinically important given that 280 
these trajectories would be indistinguishable on the basis of their ADHD symptoms in 281 
early childhood, although this would need replicating in a clinical sample. 282 
As well as being associated with ADHD genetic risk, we also found the 283 
persistent ADHD trajectory class to be strongly associated with multi-morbidity - low 284 
IQ, social communication problems, pragmatic language impairment and conduct 285 
problems in childhood. Individual childhood co-morbidities have been implicated as 286 
possible predictors of ADHD persistence14 but a global burden of multi-morbidity has 287 
not previously been assessed. Although highest in the persistent class, multi-288 
morbidity was also elevated in the childhood-limited class. ADHD shares genetic 289 
liability with childhood neurodevelopmental traits and conduct problems in the 290 
general population21,22,24 and this study shows ADHD PRS to be associated with 291 
multi-morbidity in these domains. Thus it is plausible that multi-morbidity might be an 292 
observable early phenotype marker of this loading and be associated with ADHD 293 
developmental trajectories. When controlling for multi-morbidity, ADHD PRS was no 294 
longer associated with persistence compared to childhood-limited symptoms – 295 
suggesting that the overall childhood burden of neurodevelopmental morbidity may 296 
be a phenotypic correlate, and perhaps for now a better index, of a higher genetic 297 
loading. Further work will be needed to assess the predictive value of multi-298 
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morbidity. Although this is a population-based sample, the findings highlight the likely 299 
developmental, biological, and clinical importance of multi-morbidity, an issue that 300 
until now has been considered a healthcare problem in old age.46,47 In clinical 301 
settings, typically we use a hierarchical approach to simplify and reduce the number 302 
of diagnoses. Assessing and describing multi-morbidity are therefore not easily 303 
achieved with current approaches, yet might be very important for clinical reasons 304 
and for scientific research.  305 
Recent work has suggested that some forms of ADHD emerge in adult life.5-7 306 
Although our trajectory analyses did not identify an adolescent-onset class, using an 307 
alternative method for defining ADHD course, we identified a subgroup of around 308 
2.5% of individuals who had elevated levels of ADHD traits at age 17 but not age 7 309 
years. While our study focused on an earlier age, in-line with the observation made 310 
by Moffitt and colleagues, this adolescent-onset subgroup did not show elevated 311 
ADHD genetic risk scores.5 While it is possible this is due to low PRS power, we did 312 
find an association for the persistent subgroup, despite this being smaller. This is 313 
now the fourth population study which suggests that a substantial proportion of 314 
adolescents/young adults with ADHD have onset at later ages and that finds a very 315 
low rate of ADHD persistence; moreover our study finds this pattern when using the 316 
same informant (parent) at both time-points. 317 
Our findings should be considered in light of some limitations. ALSPAC is a 318 
longitudinal birth cohort study with non-random attrition, and more complete data are 319 
likely to have been available for individuals with lower levels of psychopathology as 320 
well as PRS.48 However, we used FIML which fits the model to the non-missing 321 
values for each observation, allowing the use of all cases including those with 322 
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missing data.49 Results using an alternative method examining two time-points (ages 323 
7 and 17 years) in individuals with complete data revealed the same pattern of 324 
higher ADHD PRS for children with persistent ADHD traits. In addition, we used a 325 
questionnaire measure to investigate ADHD symptom trajectories, which may not 326 
generalize to ADHD diagnosis although the SDQ cut-point is well validated against 327 
diagnosis. Further, due to current discovery sample sizes, psychiatric PRS currently 328 
explain only a small proportion of the heritability and of phenotypic variance and are 329 
therefore underpowered (around 0.60 for the analysis using two-time-points).35 330 
However our intention was not to explain substantial proportions of phenotype 331 
variance, but to use PRS as a molecular index of common genetic loading. Finally, 332 
ADHD data in ALSPAC were only available up to age 17 years and future work is 333 
needed into environmental factors that may also contribute to the developmental 334 
course of ADHD. 335 
Conclusion 336 
We found ADHD genetic risk to be associated with the developmental course of 337 
ADHD traits from early childhood to adolescence in the general population: 338 
specifically, ADHD genetic loading was highest in individuals with persistent 339 
symptoms. Genome-wide association studies may benefit from deeper phenotyping 340 
of cases to characterize the developmental course of psychiatric disorders. ADHD 341 
persistence was also associated with a higher multi-morbidity of childhood 342 
neurodevelopmental impairments and conduct problems, which may be a phenotypic 343 
correlate of genetic loading and help to identify children with ADHD who are most 344 
likely to show persistence into adolescence.   345 
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Figure 1. Probability of being in the high-scoring range for ADHD symptoms, by latent class
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Figure 2. Mean ADHD polygenic risk score (PRS) by ADHD subgroup, based on two 
time-points (age 7 and 17 years) with 95% confidence interval error bars  
 
 
Legend: ADHD = Attention Deficit Hyperactivity Disorder; PRS = polygenic risk 
score. ADHD Subgroups based on two time-points (age 7 and 17 years) with 95% 
confidence interval error bars 
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Table 1: Associations between psychiatric polygenic risk scores and all ADHD latent trajectory classes  
 Mean (SE) Overall test  
Polygenic risk score Low Intermediate Childhood-limited Persistent χ2(3) p 
ADHD -0.018 (.014) 0.054 (.055) 0.017 (.060) 0.254 (.069) 7.83 0.05 # 
Schizophrenia -0.008 (.014) 0.026 (.054) 0.037 (.059) 0.064 (.072) 0.44 0.93 
Bipolar disorder -0.003 (.014) -0.022 (.055) 0.059 (.066) 0.018 (.070) 1.15 0.77 
Depression -0.011 (.014) 0.022 (.055) 0.067 (.060) 0.092 (.071) 1.105 0.78 
#Higher ADHD polygenic risk scores in the persistent compared to low, intermediate and childhood-limited classes (χ2(1)=4.70-
14.67, p<0.001-0.030).  
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Table 2: Associations between co-occurring childhood characteristics at aged 7 years and ADHD trajectory class  
 Proportion (95% CI) Overall test  
 
 Low Intermediate Childhood-limited Persistent χ2(3) p 
Low IQ 5.4%  (4.8-6.0) 11.4%  (8.1-14.7) 11.7%  (7.8-15.6) 21.4%  (15.5-27.3) 12.76 0.005 # 
Social-communication problems 3.4%  (3.0-3.8) 19.9%  (16.0-23.8) 22.9%  (18.2-27.6) 53.1%  (46.6-59.6) 103.50 <0.001 # 
Pragmatic language impairment 1.2%  (1.0-1.4) 7.7%  (5.0-10.4) 10.3%  (7.0-13.6) 27.8%  (22.1-33.5) 36.51 <0.001 # 
Conduct problems 6.7%  (6.1-7.3) 21.1%  (17.0-25.2) 27.5%  (22.6-32.4) 42.0%  (35.7-48.3) 56.62 <0.001 # 
Multi-morbidity        
 More than 1 additional problem 1.7%  (1.3-2.1) 13.1%     (8.6-17.6) 16.1%  (10.8-21.4) 42.5%  (33.9-51.1) 38.93 <0.001 # 
 More than 2 additional problems 0.2%  (0.0-0.4) 2.8%  (0.6-5.0) 3.4%  (0.7-6.1) 17.8%  (11.3-24.3) 17.31 0.001 # 
#Greater proportion in the persistent compared to low, intermediate and childhood-limited classes (χ2(1)=6.73-225.86, p<0.001-
0.009) and in the intermediate and childhood-limited compared to low class (χ2(1)=5.25-68.15, p=<0.001-0.02).   
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Table 3: Associations between psychiatric polygenic risk scores and ADHD symptoms at ages 7 and 17 years  
 Mean (SE) Overall test  
Polygenic risk score Low Childhood-limited Persistent Adolescent-onset F(3,3644) p 
ADHD -0.035 (.018) 0.043 (.061) 0.252 (.102) 0.101 (.104) 3.01 0.03 # 
Schizophrenia -0.035 (.018) -0.014 (.058) 0.098 (.107) 0.050 (.118) 0.66 0.58 
Bipolar disorder -0.001 (.018) 0.081 (.061) 0.117 (.120) -0.133 (.107) 1.43 0.23 
Depression -0.017 (.018) 0.089 (.057) 0.036 (.130) -0.196 (.108) 2.01 0.11 
*p<0.05. #Higher ADHD polygenic risk scores in the persistent compared to low group (B=0.29, SE=0.11, p=0.01) (see Figure 2). 
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Supplementary materials 1 
ALSPAC genotyped data 2 
In total 9912 ALSPAC children were genotyped, of whom 8365 passed quality 3 
control. Of these, 6700 had ADHD symptoms data at two-time points and were 4 
therefore included in this study. Full genotyping details and individual exclusion 5 
criteria are described elsewhere.1 Known autosomal variants were imputed with 6 
MACH 1.0.16 Markov Chain Haplotyping software2, 3 using CEPH individuals from 7 
phase 2 of the HapMap project (HG18) as a reference set (release 22) resulting in a 8 
total N=2,543,887 SNPs. Dosage data were transformed from MACH output to 9 
PLINK format using fcGENE.4 After quality control exclusions (call rate <95%, MAF 10 
<1%, HWE P>5x10-7, R2≥.7) there were 1,813,169 autosomal SNPs. EIGENSTRAT 11 
principal components analysis was used to generate the top 100 components after 12 
the removal of known regions of long linkage disequilibrium in the data.5, 6 13 
EIGENSTRAT analysis revealed no additional obvious population stratification and 14 
genome-wide analyses with other phenotypes indicate a low lambda. Previous work 15 
has included the top 10 EIGENSTRAT principal components analysis in secondary 16 
analyses7. We investigated whether these may need to be included in our analyses 17 
by testing for differences in these 10 principal components across our outcome 18 
variables: we found weak evidence of differences between the ADHD trajectories 19 
(χ2(3)=0.05-2.80, p=0.42-1.00) or between groupings of individuals using ADHD cut-20 
points at two time points (F(3,3644)=0.11-2.50, p=0.06-.96). EIGENSTRAT principal 21 
components were therefore not included as covariates in our analyses.  22 
Mental disorder risk alleles were identified from the Psychiatric Genetic 23 
Consortium (PGC) meta-analysis of case-control GWAS of ADHD (5,621 cases and 24 
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13,589 controls/pseudo-controls), schizophrenia (35,476 cases and 46,839 controls), 25 
bipolar disorder (7,481 cases and 9,250 controls) and depression (9,240 cases and 26 
9,519 controls).8-13 PGC SNPs were limited to those that passed an imputation 27 
quality control threshold akin to that set for the target sample (INFO score >=0.7). 28 
Autosomal SNPs that were present in both the target and discovery sample 29 
were limited to those in relative linkage equilibrium using the --clump command in 30 
PLINK12, 14 with an R2 threshold of .25 and a distance threshold of 500kb, retaining 31 
SNPs with the lowest association p-value. In-line with previous work,15 for 32 
schizophrenia PRS, only a single SNP within the extended major histocompatibility 33 
complex (MHC; chromosome 6: 25-34Mb) was included due to the high linkage 34 
disequilibrium (LD) within this region. This resulted in 153,652, 185,051, 149,512, 35 
and 157,210 clumped SNPs for ADHD, schizophrenia, bipolar disorder and 36 
depression respectively. These were used to generate polygenic risk scores using 37 
the --score command. Scores were calculated as the mean number of risk alleles 38 
weighted by effect size (log odds ratio). PRS were standardized using Z-score 39 
transformation for those with genetic data included in this study (N=6664). 40 
ALSPAC ADHD symptoms measure 41 
We used ROC curve analysis to assess the validity of the ADHD symptom subscale 42 
of the Strengths and Difficulties Questionnaire (SDQ)16 in detecting a DSM-IV ADHD 43 
diagnosis. ADHD diagnosis was assessed using parent reports of the Development 44 
and Well-Being Assessment, a well-established research diagnostic assessment.17 45 
Diagnoses were generated originally using computer generated diagnoses designed 46 
to complement clinician diagnoses and for examining risk factors.18 Children were 47 
defined as having a diagnosis if they were in the highest computer predicted band 48 
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(70% of children in this band predicted to have disorder). Using the SDQ ‘abnormal’ 49 
cut-point of ≥7, the area under the curve was 0.88. Of those with who had a 50 
diagnosis, around 86% reached the SDQ cut-point (sensitivity) and of those who did 51 
not have a diagnosis around 90% did not reached the SDQ cut-point (specificity); of 52 
those who reached the SDQ cut-point, 6% had a diagnosis (positive predictive value) 53 
and of those who did not reach the SDQ cut-point 99.9% did not have a diagnosis 54 
(negative predictive value), which reflect the low prevalence of ADHD diagnosis in 55 
this sample. 56 
Additional analyses: grouping individuals using ADHD cut-points at two time-57 
points 58 
We grouped individuals based on parent rated Strengths and Difficulties 59 
Questionnaire16 responses at two-ages to categorize individuals as low, childhood-60 
limited, persistent or adolescent-onset, in-line with definitions in the main manuscript. 61 
a) Age 4 and 17 years 62 
Using data from age 4 and 17 years (N=4915), 83.9% of individuals were 63 
categorized as low, 10.7% childhood-limited, 1.9% persistent and 2.8% adolescent-64 
onset (.7% excluded as they reached the cut-point at age 17 but were borderline at 65 
age 4). ADHD PRS differed across the subgroups (F(3,3677)=4.71, p=0.003). PRS 66 
for schizophrenia, bipolar disorder and depression did not differ by subgroup 67 
(F(3,3677)=0.43-1.05, p=0.37-.73). Specifically, there was evidence of higher ADHD 68 
PRS in the persistent compared to the low (B=0.34, SE=0.12, p=0.01). There was 69 
evidence of higher ADHD PRS in the child-hood limited compared to the low 70 
(B=0.12, SE=0.05, p=0.03), as shown in Figure S2a. 71 
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b) Age 12 and 17 years 72 
Using data from age 12 and 17 years (N=4953), 90.9% of individuals were 73 
categorized as low, 3.9% childhood-limited, 2.2% persistent and 2.4% adolescent-74 
onset (.6% excluded as they reached the cut-point at age 17 but were borderline at 75 
age 12). ADHD PRS differed across the subgroups (F(3,3746)=7.93, p<0.001). PRS 76 
for schizophrenia, bipolar disorder and depression did not differ by subgroup 77 
(F(3,3746)=0.60-1.00, p=0.39-.62). Specifically, there was evidence of higher ADHD 78 
PRS in the persistent compared to the low (B=0.51, SE=0.11, p<0.001), childhood-79 
limited (B=0.43, SE=0.15, p=0.004) and adolescent-onset (B=0.70, SE=0.19, 80 
p<0.001) subgroups, as shown in Figure S2b. 81 
Age 7 and 17: inattentive and hyperactive-impulsive symptoms separately 82 
Individuals were also grouped based on parent rated Strengths and Difficulties 83 
Questionnaire16 responses at ages 7 and 17 years separately for inattentive and 84 
hyperactive-impulsive symptoms. Inattentive scores were the summed items ‘Easily 85 
distracted, concentration wanders’ and ‘Sees tasks through to the end’ (reverse 86 
coded) (possible range 0-4). Hyperactive-inattentive scores were the summed items 87 
‘Restless, overactive’, ‘Constantly fidgeting or squirming’ and ‘Thinks things out 88 
before acting’ (reverse coded) (possible range 0-6). Somewhat in-line with the cut-89 
point for abnormal scores for the total subscale being 7/10 (70% of total possible 90 
score)16 the cut-point for inattentive and hyperactive-impulsive symptoms were 91 
selected as 3 and 4 respectively. 92 
c) Inattentive symptoms 93 
32 
 
For inattentive symptoms, (N=4757), 77.2% of individuals were categorized as low, 94 
8.3% childhood-limited, 5.6% persistent and 8.9% adolescent-onset. ADHD PRS 95 
differed across the subgroups (F(3,3623)=4.34, p=0.01). PRS for schizophrenia, 96 
bipolar disorder and depression did not differ by subgroup (F(3,3623)=0.18-1.92, 97 
p=0.12-91). Specifically, there was evidence of higher ADHD PRS in the persistent 98 
compared to the low (B=0.23, SE=0.07, p=0.001), as shown in Figure S2c. 99 
d) Hyperactive-impulsive symptoms 100 
For hyperactive-impulsive symptoms (N=4535) 82.2% of individuals were 101 
categorized as low, 11.8% childhood-limited, 2.9% persistent and 3.2% adolescent-102 
onset. ADHD PRS differed across the subgroups (F(3,3452)=3.06, p=0.03). PRS for 103 
schizophrenia, bipolar disorder and depression did not differ by subgroup 104 
(F(3,3452)=0.30-1.62, p=0.18-.83). Specifically, there was evidence of higher ADHD 105 
PRS in the persistent compared to the low (B=0.25, SE=0.10, p=0.02) subgroup, as 106 
shown in Figure S2d.107 
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a) Individuals with ADHD symptom data at 
each time point 
b) Number of time-points individuals had 
ADHD symptom data available 
  
NB. Individuals with ADHD symptom data at fewer time points were less likely to be 
in the low class (mean number of time-points 5.38) compared to the intermediate, 
childhood-limited or persistent classes (mean number of time-points = 5.19, 5.14 and 
4.96 respectively) (χ2(1)=3.72-14.44, p<0.001-.054). 
Figure S1. Number of individuals with ADHD symptom data at each time point
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a) Age 4 and 17 years b) Age 12 and 17 years 
  
c) Age 7 and 17 years: Inattentive symptoms d) Age 7 and 17 years: Hyperactive-impulsive symptoms 
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Figure S2. Mean ADHD polygenic risk score (PRS) by subgroup, based on two time-points with 95% confidence interval error bars 
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